Shares of Mateon Therapeutics, Inc. (OTCMKTS:MATN – Get Free Report) crossed above its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $0.03 and traded as high as $0.04. Mateon Therapeutics shares last traded at $0.04, with a volume of 40,045 shares.
Mateon Therapeutics Price Performance
The company’s 50-day moving average price is $0.03 and its two-hundred day moving average price is $0.03.
About Mateon Therapeutics
Mateon Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-beta, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus.
See Also
- Five stocks we like better than Mateon Therapeutics
- Low PE Growth Stocks: Unlocking Investment Opportunities
- 3 Undervalued Stocks You Can Buy at a Discount Now
- Most Volatile Stocks, What Investors Need to Know
- AMD Stock: Can the PC Refresh Cycle Spark a Rally?
- Canada Bond Market Holiday: How to Invest and Trade
- Micron Stock Spikes 7%—3 Key Catalysts Behind the Move
Receive News & Ratings for Mateon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mateon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
-logo-1200x675.png&h=54&w=95&zc=2){kind=logo}
